Lyophilized Stem Cell Secretome for Ocular Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative medicine therapies based on stem cells face challenges in production, storage, and manufacturing quality control, particularly for ocular conditions, where there is a need for therapies that can effectively target and heal difficult-to-reach sensory tissues.
Innovation Solution
The development of reconstituted lyophilized mesenchymal stem cell secretome compositions, which include specific trophic factors, cytokines, and other bioactive molecules, formulated for topical administration or subconjunctival injection to promote ocular wound healing and reduce neovascularization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live stem cell-based therapies are produced and stored, then regenerative capacity is maintained, but production and storage difficulty increases and therapeutic potency becomes variable
Solution Approach 1:
The patent extracts the therapeutic components from live stem cells by harvesting the secretome (extracellular secretions including cytokines, growth factors, and other bioactive molecules). This separation allows the therapeutic activity to be maintained without requiring live cells, thereby resolving the contradiction between maintaining therapeutic potency and the difficulties of producing/storing live cell therapies.
Solution Approach 2:
The patent transforms the stem cell therapy from a live cell-based system to a lyophilized (freeze-dried) secretome composition. This parameter change in the physical state and form of the therapeutic agent enables improved storage stability and eliminates the variability in potency associated with live cell storage and handling.
2Reliability
If stem cell therapies are implanted, then regenerative effect is achieved, but susceptibility to host immune system attack increases
Solution Approach 1:
By extracting and utilizing only the secretome components (cytokines, growth factors, and bioactive molecules) rather than implanting live stem cells, the patent eliminates the immune recognition and rejection problems associated with foreign cells. The secretome components can be delivered without triggering host immune attacks while maintaining regenerative effects.
3Reliability
If live stem cells are used for therapy, then regenerative capacity is maintained, but difficulty in assessing potency and controlling dosing increases
Solution Approach 1:
The patent creates a standardized copy of the therapeutic activity in the form of a defined secretome composition with controlled concentrations of bioactive molecules. This standardized formulation allows for precise dosing control and potency assessment through quantitative analysis of the secretome components, eliminating the variability inherent in live cell-based therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions demonstrate enhanced stability and bioactivity, effectively promoting ocular wound healing, reducing scarring, and preserving vision by delivering a therapeutic payload to sensitive ocular tissues.
Implementation Method 1
lyophilized mesenchymal stem cell secretome compositions
Implementation Method 2
reconstituted lyophilized mesenchymal stem cell secretome compositions
Data Source
AI summary
The present application provides methods and processes for making and using a lyophilized mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the reconstituted lyophilized mesenchymal stem cell secretome described herein.